Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and ...

Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...

The firm said the clinical trial pause is temporary as an independent data monitoring committee finalizes its analysis for submission to regulators.

Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a ...

Singapore VC firm Vickers Venture Partners files for $180M IPO for second SPAC, Vickers Vantage Corp. II, following 2022 ...

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...

In a heartwarming homecoming celebration, Mackenzie returned to the hospital with her family to commemorate not just her milestone birthday, but also the hospital's incredible journey in providing ...

Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...

WALTHAM, MASSACHUSETTS / ACCESS Newswire / April 4, 2025 / Today at the Bio-IT World Conference & Expo in Boston, Data4Cure, Inc. will present its latest advancements in AI-driven data integration and ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...

Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.